A three-month programme, comprising moderate aerobic and strengthening exercises, conducted for 50-60 minutes three times per week, proved not only to be safe and beneficial both physically and in terms of quality of life for patients, but was also associated with a stabilising effect in disease activity measured by DAS28*. During the Portuguese study's three month period, researchers observed the following:
19% improvement in the walk time test (p=0.063)
62% of patients reported a reduced need for daily corticosteroid intake, from a mean dosage of 5.3mg/day of prednisone to 3.1mg/day (p=0.038)
32% of patients reported stopping concurrent NSAID (non-steroidal anti-inflammatory drug) treatment altogether following the exercise programme (p=0.083)
Mean LDL (low-density lipoprotein) cholesterol increased from 90mg/dl to 125mg/dl (p=0.018)
40% improvement in the Depression Anxiety Stress Scales (DASS), a self-reported assessment of negative emotional states, with 28% in the depression and 48% in the anxiety component respectively (p=0.078)
Dr Miguel Sousa of Instituto Português de Rheumatology, Lisbon, Portugal, who led the study, said: "When joints are stiff and painful, proactively taking exercise might seem undesirable for people with RA. However, our study has demonstrated that regular and supervised moderate aerobic workouts and strengthening exercises may be extremely beneficial for both a patient's physical and mental health, with a corresponding effect on quality of life. The challenge for physicians is to provide suitable motivation and reassurance to their RA patients in order that they initiate and stick with such a programme."
The observational longitudinal study followed eight physically-inactive patients (7 female; mean age of 59 (46-71) years; mean disease duration of 16 (3-30) years) with relatively stable RA (stable medication taken for at least three months; mean dose of methotrexate 17.5mg/week) for three months.
* DAS28 (Disease Activity Score) is an index used by physicians to measure how active an individual's RA is. It assesses number of tender and swollen joints (out of a total of 28), the erythrocyte sedimentation rate (ESR, a blood marker of inflammation), and the patient's 'global assessment of global health'. A higher score indicates more active disease.For further information on this study, or to request an interview with the study lead, please do not hesitate to contact the EULAR congress press office on:
In line with The European Union of Medical Specialists (UEMS), EULAR defines rheumatology as including rheumatic diseases of the connective tissue, locomotor and musculoskeletal systems.
The aims of EULAR are to stimulate, promote, and support the research, prevention, treatment and rehabilitation of rheumatic diseases. To this end, EULAR fosters excellence in education and research in the field of rheumatology. It promotes the translation of research advances into daily care and fights for the recognition of the needs of people with rheumatic diseases.
In 2009, The EULAR Executive Committee launched the EULAR Orphan Disease Programme (ODP) which aims to provide funding to research programmes focused on furthering understanding of the disease mechanisms behind systemic sclerosis. Please see www.eular.org for further information.
Diseases of the bone and joints such as rheumatoid arthritis and osteoarthritis cause disability in 4-5% of the adult population and are predicted to rise as people live longer.
As new treatments emerge and cellular mechanisms are discovered, EULAR 2009 is set to be the biggest rheumatology event in Europe with over 13,500 scientists, physicians, allied health professionals, and related audiences in attendance from over 100 countries. Over the course of the congress, more than 300 oral and 1700 poster abstract presentations will be featured, with 780 invited speaker lectures taking place in more than 150 sessions.
Rory Berrie | EurekAlert!
Monitoring the heart's mitochondria to predict cardiac arrest?
21.09.2017 | Boston Children's Hospital
Highly precise wiring in the Cerebral Cortex
21.09.2017 | Max-Planck-Institut für Hirnforschung
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
21.09.2017 | Physics and Astronomy
21.09.2017 | Life Sciences
21.09.2017 | Health and Medicine